Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Short Interest Report for October

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totaling 23,906 shares, a decrease of 73.4% from the September 30th total of 89,977 shares. Based on an average trading volume of 49,073 shares, the short-interest ratio is currently 0.5 days. Currently, 1.5% of the company’s shares are sold short.

Global X Genomics & Biotechnology ETF Trading Up 1.4%

GNOM stock traded up $1.03 during trading on Thursday, hitting $72.54. The company had a trading volume of 42,404 shares, compared to its average volume of 21,134. The stock has a market cap of $116.06 million, a PE ratio of -31.00 and a beta of 1.17. The business has a 50-day moving average of $66.69 and a 200-day moving average of $53.53. Global X Genomics & Biotechnology ETF has a one year low of $41.16 and a one year high of $74.19.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

Several large investors have recently modified their holdings of GNOM. Bank of America Corp DE raised its stake in Global X Genomics & Biotechnology ETF by 67.8% during the first quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock worth $5,240,000 after buying an additional 48,394 shares during the last quarter. Wealth Management Partners LLC lifted its holdings in Global X Genomics & Biotechnology ETF by 143.3% in the third quarter. Wealth Management Partners LLC now owns 24,677 shares of the company’s stock valued at $1,739,000 after buying an additional 14,533 shares during the period. Polaris Financial Partners acquired a new position in Global X Genomics & Biotechnology ETF in the third quarter valued at $1,067,000. Farther Finance Advisors LLC bought a new stake in Global X Genomics & Biotechnology ETF during the third quarter valued at $257,000. Finally, Halbert Hargrove Global Advisors LLC bought a new stake in Global X Genomics & Biotechnology ETF during the third quarter valued at $77,000. 56.95% of the stock is currently owned by institutional investors and hedge funds.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.